|
Compound class:
Antibody
Comment: Tizetatug rezetecan (SHR-A1921) is an antibody-drug conjugate (ADC) that is composed of a humanized anti-TROP2 IgG1 monoclonal antibody attached to a DNA topoisomerase I by a cleavable linker. TROP2 is encoded by the TACSTD2 (tumor associated calcium signal transducer 2) gene. The TROP2 protein is overexpressed on the surface of many solid tumour types, and is an active therapeutic target for the development of anti-neoplastics. Sacituzumab govitecan (Trodelvy®) was the first monoclonal in this class to be approved by the FDA (in 2020).
|
